Price (delayed)
$19.91
Market cap
$239.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.79
Enterprise value
$230.23M
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is
There are no recent dividends present for CRBP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.